News on HIV Drug Resistance in New Antiretrovirals From the XVI International HIV Drug Resistance Workshop (July 24, 2007)
With every new medication it's critical to understand which mutations are predictive of a less than optimal response. In this report on Doug Richman's review from the XVI International HIV Drug Resistance Workshop, Mark Holodniy, M.D., discusses genotypic and phenotypic assays associated with R5 inhibitors and HIV drug resistance associated with the following antiretrovirals in development: etravirine, raltegravir, elvitegravir and maraviroc.
In 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, from TheBodyPRO.com
The Body is a service of Remedy Health Media, LLC, 500 5th Avenue, 19th Floor, New York, NY 10110. The Body and its logos are trademarks of Remedy Health Media, LLC, and its subsidiaries, which owns the copyright of The Body's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.